Bayer Raises FY Group Sales Outlook; Allocates Extra EUR 1.2 Bln For Glyphosate Litigation

Bayer AG has raised its full-year 2025 financial guidance across Group sales, EBITDA before special items, and core earnings per share, driven by stronger-than-expected performance in its Pharmaceuticals division during the first half. The company now forecasts full-year sales between 46 billion euros and 48 billion euros and core EPS of 4.80 euros to 5.30 euros. This positive revision comes despite establishing an additional 1.2 billion euros in provisions for Roundup litigation, bringing the total to approximately 1.7 billion euros, and anticipating significant negative currency effects on its top and bottom lines. Second-quarter 2025 results showed Group sales of 10.7 billion euros and core EPS of 1.23 euros.

Analysis

Bayer AG has issued an upward revision to its full-year 2025 guidance, signaling stronger-than-anticipated operational performance driven by its Pharmaceuticals division. The company now projects Group sales between €46 billion and €48 billion and core earnings per share in the range of €4.80 to €5.30. This improved outlook is particularly notable as it absorbs several significant headwinds, including an additional provision of approximately €1.2 billion for the ongoing Roundup litigation and substantial negative currency effects expected to reduce sales by around €2 billion and EBITDA by €500 million. While preliminary Q2 2025 core EPS rose to €1.23, the forecasts for full-year free cash flow (€1.5-2.5 billion) and net financial debt (€31.0-32.0 billion) remain unchanged, suggesting that the underlying operational beat may be offset by litigation payments or other capital allocations. The guidance also accounts for projected impacts from geopolitical developments, including potential US tariffs, providing a degree of certainty to the revised forecast ahead of the detailed Q2 results on August 6, 2025.

Key Decisions for Investors

• The upgraded guidance, achieved despite substantial litigation provisions and currency headwinds, points to strong underlying operational momentum in the core business that could be a significant positive catalyst.
• Investors should scrutinize the upcoming full Q2 report for details on why the robust earnings upgrade did not translate into improved free cash flow or debt reduction forecasts, as this may indicate the extent to which litigation costs are consuming operational gains.
• The ongoing €1.2 billion provision for Roundup litigation remains a critical risk factor, and any further updates on the company's strategy or future liabilities in this area should be closely monitored.
• Consider the resilience of the Pharmaceuticals division as a core strength, but weigh it against the persistent financial drag from litigation and significant negative FX volatility when assessing the company's risk/reward profile.